<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065606</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180476</org_study_id>
    <nct_id>NCT05065606</nct_id>
  </id_info>
  <brief_title>Descriptive Analysis of Dual-energy Computed Tomography Exams of Adult Patients With Gout</brief_title>
  <acronym>DECTGOUT</acronym>
  <official_title>Descriptive Analysis of Soft-tissue Urate Deposits, and Bone and Joint Destruction in Dual-energy Computed Tomography Exams of Adult Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canon Medical Systems, USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to describe urate deposits (especially in terms of distribution and&#xD;
      volume) in soft tissues and bone, and joint erosions and destruction, in adult patients with&#xD;
      gout.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout is the result of hyperuricemia, itself a consequence of a disorder of purine metabolism.&#xD;
      This hypuricemia can lead to the deposition of sodium urate crystals in the soft tissues. It&#xD;
      is the deposition of sodium urate crystals in and near the joints that causes an intense&#xD;
      local inflammatory reaction with episodes of acute joint pain, swelling and functional&#xD;
      disability. In the long term, uratic concretions in the soft tissues (tophus) occur, the&#xD;
      joints are destroyed (uratic arthropathies), the kidneys also (gouty nephropathy).&#xD;
&#xD;
      Dual-energy CT (Computed Tomography) is a relatively recent technique that allows the&#xD;
      identification of certain materials through the analysis of the difference in attenuation of&#xD;
      the material exposed to two different X-ray spectra. This technique identifies the&#xD;
      crystalline component of tophus.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Soft tissue tophus description</measure>
    <time_frame>The day of the CT (computed tomography) examination</time_frame>
    <description>Description of soft tissue tophus in terms of location, size, density at high and low energy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distribution of urate deposits</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>Distribution of urate deposits in soft tissues and bone, and joint erosions and destruction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive analysis of joint erosions and destruction</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>Descrition of joint erosions and destruction :erosion size (mm) and location (joint), joint destruction (space narrowing, joint collapse, joint ankylosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the descriptive parameters on dual-energy CT with clinical data</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>to correlate the descriptive parameters on dual-energy CT with clinical data, including disease history and therapeutic management, and serum urate level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations in tophaceous burden</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>To study the variations in tophaceous burden according to the choice of technical parameters for deposit analysis.The parameters of dual energy analysis (threshold, optional filter to remove noise, gradients of dual-energy) change the quantitative value provided by the manufacturer. This outcome will be the urate volume obtained at different parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between tophus and erosions</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>To analyze the relationships between bone erosion scores and urate volume (correlation between quantitative values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of a scoring system</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>To develop and evaluate the reproducibility of a scoring system for tophaceous load and structural damage using a dual energy CT. We will try to developp a scoring system combining the tophus load (total tophus volume) and the erosion score (total erosion score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>To evaluate the bone mineral density at the distal radius and correlate it with tophaceous load and joint structural damage. A region of interest at the distal radius (one centimeter above the joint space) will be placed using the computer mouse to obtained the bone mineral density (in Hounshield unit, mean bone mineral density within the ROI (Region Of Interest)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tophus texture</measure>
    <time_frame>The day of the CT examination</time_frame>
    <description>To evaluate tophus texture. The texture of the tophus will be approached qualitatively (homogeneous/heterogeneous) and according to its density (Hounsfield unit) and to the percentage of tophus color-coded by the dual energy analyse.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gout</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual-energy computed tomography</intervention_name>
    <description>Dual-energy scanner examinations stored in the PACS (medical imagery) at Lariboisière Hospital are to be analyzed retrospectively and prospectively</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective analysis of dual-energy CT exams performed in routine care in patients with&#xD;
        gout according to ACR criteria, patients included between end of year 2016 and end of year&#xD;
        2021 (retrospective and prospective inclusion, retrospective analysis)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years old;&#xD;
&#xD;
          -  Patient with a gout according to ACR (American College of Rheumatology) criteria;&#xD;
&#xD;
          -  Affiliated with a social security scheme.&#xD;
&#xD;
          -  Dual-energy scanner examinations stored in the PACS at Lariboisière Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie BOUSSON, PUPH</last_name>
    <role>Study Director</role>
    <affiliation>APHP Lariboisière - Imagerie OstéoArticulaire,Viscérale</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valérie BOUSSON, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP Lariboisière - Imagerie OstéoArticulaire,Viscérale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie BOUSSON, PUPH</last_name>
    <phone>+33(0)149959107</phone>
    <email>valerie.bousson@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie BOUSSON, PUPH</last_name>
    <phone>+33(0)149959106</phone>
    <email>valerie.bousson@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Lariboisière - Service d'Imagerie OstéoArticulaire, Viscérale et Vasculaire</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie BOUSSON, PUPH</last_name>
      <phone>+33(0)149959107</phone>
      <email>valerie.bousson@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Benoist, CCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire Attane, CCA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie Bousson, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang-Korng Ea, PU-PH</last_name>
      <email>hang-korng.ea@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal Richette, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Bardin, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic Lioté, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aline Frazier, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Augustin Latourte, MCUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérémy Ora, PA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hang-Korng Ea, PUPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - Service de Rhumatologie</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastien Ottaviani, PH</last_name>
      <email>sebastien.ottaviani@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Dieudé, PUPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastien Ottaviani, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

